Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a randomized double-blind placebo-controlled study of BTA-C585 in an RSV human challenge model
2015-004296-77Phase 2Completed
- Sponsor
- Biota Holdings Limited
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing BTA-C585 with Placebo (2 arms). Primary endpoint: RSV viral load AUC by RT-qPCR in nasal wash. Started Nov 2015; status: completed.
02
Drugs
enzaplatovir
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2015-004296-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004296-77.